Intravenous lanadelumab for the treatment of moderately ill COVID‐19 patients
This exploratory study was evaluated using a shortened primary endpoint period. Lanadelumab showed no indication of benefit on oxygen needs or other clinical outcomes in patients with COVID-19. Lanadelumab was well tolerated throughout the trial.
Authors
- Schutgens Re
- F Van De Veerdonk
- Hassing Rj
- Christine C. A. van Linge (ORCID: https://orcid.org/0000-0003-2787-8895)
- Roger J. M. Brüggemann (ORCID: https://orcid.org/0000-0002-7618-725X)
- Job J. Engel (ORCID: https://orcid.org/0000-0002-8648-598X)
- Kit CB Roes
- Coen Maas
- W. Joost Wiersinga
- Danique J. H. Huijbens
- Helen L. Leavis
- Ilse J. E. Kouijzer
Institutions
- Radboud University Nijmegen (NL)
- Radboud University Medical Center (NL)
- University Medical Center Utrecht (NL)
- Radboud Institute for Molecular Life Sciences (NL)
- Amsterdam University Medical Centers (NL)
- Rijnstate Hospital (NL)
- University of Amsterdam (NL)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2026-01-09
- DOI
- https://doi.org/10.1002/bcp.70438
- Primary Topic
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- ZonMw